Eli Lilly and Company

Other

Ligand Pharmaceuticals, Inc.

Dawn Alisa Brooks

Christopher J Rito

Alan M Warshawsky

Leonard Larry Winneroski, Jr

Robert J Ardecky

Samuel James Dominianni

Alexander Glenn Godfrey

Lynn Stacy Gossett

John S Tyhonas

James R McCarthy

Donald Paul Matthews

Yanping Xu

Anthony John Shuker

Pierre-Yves Michellys

David A Hay

Sarah Beth Jones

Guoxin Zhu

Scott Eugene Conner

Allie Edward Tripp

Nathan Bryan Mantlo

Carlos Lamas-Peteira

Lourdes Prieto

Jose Alfredo Martin

Rafael Ferritto Crespo

Isabel Rojo

Chahrzad Montrose-Rafezadeh

Anne-Reifel Miller

Maria Rosario Gonzales Garcia

Alicia Torrado

Maria Martin-Ortega Finger

Pierre Yves Michellys

Christopher John Rit

Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubstituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is II, alkyl or haloalkyl, R4 is II, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists

Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl, haloalkyl or phenyl; Y is an unsubstituted or substituted thiophen-2,5-diyl or phenylene; R3 is alkyl or haloalkyl; R4 is a substituted or unsubstituted phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl or benzo[1,3]dioxol-5-yl group; and R5 is H, alkyl, or aminoalkyl; are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus. 

Peroxisome proliferator activated receptor agonists

Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, &#x2014;CH&#x2014; or &#x2014;CHCH&#x2014;; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length. Phenyl Ring A is optionally substituted with up to four substituents in addition to Rand W, Ris (CH)&#x2014;CH(OR)&#x2014;(CH)E, &#x2014;(CH)&#x2550;C(OR)&#x2014;(CH)E, &#x2014;(CH)&#x2014;CH(Y)&#x2014;(CH)E or (CH)&#x2550;C(Y)&#x2014;(CH)E; wherein E is COOR, C&#x2013;Calkylnitrile, carboxamide, sulfonamide, acylsulfonamide or tetrazole and wherein sulfonamide, acylsulfonamide and tetrazole are optionally substituted with one or more substituents independently selected from: C&#x2013;Calkyl, haloalkyl and aryl-C-4-alkyl; Ris H, an aliphatic group, a substituted aliphatic group, haloalkyl, an aromatic group, a substituted aromatic group, &#x2014;COR, &#x2014;COOR, &#x2014;CONRR, &#x2014;C(S)R, &#x2014;C(S)ORor C(S)NRR, Ris H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. Y is O&#x2014;, CH&#x2014;, &#x2014;CHCH&#x2014; or CH&#x2550;CH&#x2014; and is bonded to a carbon atom in Phenyl Ring A that is ortho to R. R&#x2013;Rare independently H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. n and m are independently 0, 1 or 2 

Modulators of peroxisome proliferator activated receptors

Novel compounds that are modulators of PPAR receptors, and pharmaceutically acceptable salts, solvates and hydrates thereof, processes for making the compounds, pharmaceutical compositions containing the compounds, or pharmaceutically acceptable salts, solvates and hydrates thereof 

Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubsituted or substituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is H, alkyl or haloalkyl. R4 is H, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl, haloalkyl or phenyl; Y is an unsubstituted or substituted thiophen-2,5-diyl or phenylene; R3 is alkyl or haloalkyl; R4 is a substituted or unsubstituted phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl or benzo[1,3]dioxol-5-yl group; and R5 is H, alkyl, or aminoalkyl; are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists

Growing community of inventors

Indianapolis, IN, United States of America

Dawn Alisa Brooks